According to researchers from the University of California, diabetes drug Sitagliptin (commonly sold as Januvia ), could cause abnormalities in the pancreas . These abnormalities are regarded as risk factors for pancreatitis, and could even cause pancreatic cancer amongst long-term users.
Januvia is a type 2 diabetes drug that enhances glucagon function. The drug is prescribed due to being effective in lowering blood sugar levels amongst people with type 2 diabetes .
The lead investigator of the study, Peter Butler, reportedly commented: ” Type-2 diabetes is a lifelong disease – people often take the same drugs for many years, so any adverse effect that could over time increase the risk for pancreatic cancer would be a concern. A concern here is that the unwanted effects of this drug on the pancreas would likely not be detected in humans unless the pancreas was removed and examined.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…